Current Hepatocellular Carcinoma News and Events

Current Hepatocellular Carcinoma News and Events, Hepatocellular Carcinoma News Articles.
Sort By: Most Relevant | Most Viewed
Page 1 of 25 | 1000 Results
Acid reflux disease may increase risk of cancers of the larynx and esophagus
Results from a large prospective study indicate that gastroesophageal reflux disease (GERD), which also causes heartburn symptoms, is linked with higher risks of various cancers of the larynx (or voice box) and esophagus. The study is published early online in CANCER, a peer-reviewed journal of the American Cancer Society. (2021-02-22)

Cancer control: Non-DNA changes induce metabolism variations in hepatocellular carcinomas
Mechanisms underlying metabolic variations in hepatocellular carcinoma (HCC), a fast growing and invasive cancer, remain unclear. Now, researchers from Fudan University, China identified signatures of ''m6A,'' the most abundant ''post-transcriptional RNA modification,'' that segregate HCC into sub-types with distinct metabolic characteristics. They have also developed a novel m6A score that can quantify such modifications and aid risk assessment, prediction of prognosis, and response to treatment in patients with HCC. (2021-02-22)

MSK physician shares kidney cancer research at annual ASCO GU Symposium
Memorial Sloan Kettering's Robert Motzer presented positive data from a phase III randomized study that assessed two different treatment combinations as first-line therapies that may benefit people with advanced kidney cancer. (2021-02-16)

Ionic liquid uniformly delivers chemotherapy to tumors while destroying cancerous tissue
A Mayo Clinic team, led by Rahmi Oklu, M.D., Ph.D., a vascular and interventional radiologist at Mayo Clinic, in collaboration with Samir Mitragotri, Ph.D., of Harvard University, report the development of a new ionic liquid formulation that killed cancer cells and allowed uniform distribution of a chemotherapy drug into liver tumors and other solid tumors in the lab. This discovery could solve a problem that has long plagued drug delivery to tumors. (2021-02-11)

Oncotarget: Combination of copanlisib with cetuximab improves tumor response
''These data support further investigation of PI3K inhibition in HNSCC and suggests gene expression patterns associated with PI3K signaling'' (2021-02-10)

Drug 'breakthrough' gives longest-ever survival in nonresectable liver cancer patients
New follow-up data from a landmark study of liver cancer patients treated with a combination of an immunotherapy drug (atezolizumab) and a monoclonal antibody (bevacizumab) has shown the longest-ever survival time in a frontline phase 3 trial of systemic therapy in advanced hepatocellular carcinoma (HCC), demonstrating a 'major breakthrough' in the field. (2021-02-05)

Liver cancer 'signature' in gut holds clues to cancer risk
People with non-alcohol-related liver cancer have a unique gut microbiome profile which could help predict disease risk, a new UNSW Sydney study has found. (2021-02-03)

Yale researchers develop injection to treat skin cancer
Yale researchers are developing a skin cancer treatment that involves injecting nanoparticles into the tumor, killing cancer cells with a two-pronged approach, as a potential alternative to surgery. (2021-02-02)

Oncotarget: Neuroendocrine carcinoma of uterine cervix findings shown by MRI
''The Oncotarget author's findings show that MRI is reliable for T staging of cervical NEC'' (2021-02-01)

Reduced-dose RT with Cisplatin improves outcomes for HPV-associated oropharyngeal carcinoma
A combination of reduced-dose radiotherapy using intensity-modulated radiotherapy (IMRT) combined with concurrent cisplatin met the threshold for disease control and quality of life compared to the standard of care for good-risk patients with HPV-associated oropharyngeal squamous cell carcinoma on the NRG Oncology clinical trial NRG-HN002. (2021-01-29)

Oncotarget: Prognostic biomarker for patients with hepatocellular carcinoma
Reduced expression of TBX15 in tumor tissue represents a potential biomarker for predicting poor survival of patients with HCC (2021-01-25)

Male breast cancer patients face high prevalence of heart disease risk factors
Male breast cancer patients were found to have a high prevalence of cardiovascular conditions, in a small study of this rare patient population presented at the American College of Cardiology's Advancing the Cardiovascular Care of the Oncology Patient Virtual course. (2021-01-25)

ACSL1 as a main catalyst of CoA conjugation of propionic acid-class NSAIDs in liver
Researchers from Kanazawa University have found that propionic acid-class nonsteroidal anti-inflammatory drugs (NSAIDs), including ibuprofen, form ''conjugates'' with coenzyme A (CoA) by one of the acyl-CoA synthetases, ACSL1, in liver. These conjugates have the covalent binding ability to cellular proteins that may lead to liver injury, a rare severe side effect of NSAID treatment. This knowledge could help pharmaceutical companies to generate pain control options with fewer risks of severe side effects. (2021-01-22)

Potential combined drug therapy for lung cancer
Researchers at Kanazawa University report in Clinical Cancer Research that in the most common type of lung cancer, certain secondary mutations occurring with another gene alteration known as ALK make the efficacy of alectinib, an otherwise commonly used drug for treating lung cancer, become unfavorable. Combining alectinib with another kind of drug can overcome this adverse effect, however. (2021-01-22)

Armouring anti-cancer T cells against immunosuppressants
New 'armoured' T cells attack cancer without being suppressed by drugs given to transplant patients to avoid organ rejection. (2021-01-18)

Scoring system to redefine how U.S. patients prioritized for liver transplant
Researchers with Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine are collaborating with faculty at the University of Pennsylvania to develop a risk score that more comprehensively prioritizes liver cancer patients for transplantation. (2021-01-13)

Liver cancer cells manipulate stromal cells involved in fibrosis to promote tumor growth
Researchers led by Osaka University have found that liver cancer cells induce autophagy in hepatic stellate cells, causing them to produce a growth factor called GDF15 that promotes tumor growth. GDF15 was more highly expressed in tumor tissue than normal liver tissue, and patients with higher levels of GDF15 had a poorer prognosis. New therapies targeting GDF15 may help prevent the development and proliferation of hepatocellular carcinoma. (2021-01-06)

Sixfold increase in risk
A research team at the Technical University of Munich (TUM) has quantified the effects of an infection with the Human Immunodeficiency Virus (HIV) on the development of cervical cancer. Their results show that the risk of developing cervical cancer is six times higher in women who are infected with HIV. Southern and Eastern Africa are particularly affected. (2020-12-21)

A first-in-human clinical trial shows microbubbles augments radiation in liver cancer patients
Bursting gas-filled microbubbles using ultrasound waves sensitizes tumors to targeted radiation, reducing tumor growth and improving overall survival after treatment. (2020-12-15)

USPSTF statement on screening for hepatitis B virus infection in adolescents, adults
The US Preventive Services Task Force (USPSTF) recommends screening for hepatitis B virus infection in adolescents and adults at increased risk for infection.  (2020-12-15)

Researchers discover treatment that suppresses liver cancer
Researchers from the University of Missouri School of Medicine have discovered a treatment combination that significantly reduces tumor growth and extends the life span of mice with liver cancer. This discovery provides a potentially new therapeutic approach to treating one of the leading causes of cancer-related death worldwide. (2020-12-08)

A library of mice to look up the best liver cancer treatment
Researchers from Osaka University have developed a mouse model that reproduces the real-world variety of genetic drivers of liver cancer, and used this model to discover that tumors driven by the gene FGF19 are especially vulnerable to treatment with the drug lenvatinib. They also found a serum biomarker that may help indicate which patients have this specific type of cancer, potentially leading to improved treatment selection and outcomes. (2020-12-07)

β-AR agonist therapy puts the brakes on oral cancer progression
Oral cancer has a high mortality rate that is mainly attributed to metastasis. Researchers from Tokyo Medical and Dental University (TMDU) screened a panel of small chemical compounds for their ability to inhibit metastasis in oral cancer, identifying β2?AR-agonist isoxsuprine as a potential candidate. Treatment of various oral cancer cells with isoxsuprine suppressed their motility, while tumor size was significantly decreased in isoxsuprine-treated mice, suggesting that β-AR-agonist therapy could be an effective new treatment for oral cancer. (2020-12-03)

Combination therapy might improve outcomes in treatment-resistant liver cancer
A combination cancer therapy that is effective against treatment-resistant hepatocellular carcinoma (HCC) by inhibiting tumor growth and increasing survival has been identified by researchers at Massachusetts General Hospital. The dual therapy -- which combines the multikinase inhibitor drug regorafenib to ''reprogram'' the tumor immune microenvironment, and programmed cell death 1 antibodies to stimulate anti-tumor immunity -- improved survival in mouse models of HCC beyond what each therapy could have achieved alone. (2020-11-30)

Plant-based diet ramps up metabolism, according to new study
A plant-based diet boosts after-meal burn, leads to weight loss, and improves cardiometabolic risk factors in overweight individuals, according to a new randomized control trial published in JAMA Network Open by researchers with the Physicians Committee for Responsible Medicine. (2020-11-30)

Scientists regenerate skin with stem cells to see how DNA defects in kids cause cancer
Physicians and scientists at Cincinnati Children's Hospital Medical Center used new stem cell technology to regenerate and study living patient-specific skin in the lab, giving them a precise close up view of how inherited DNA defects cause skin damage and deadly squamous cell carcinoma in children and young adults with Fanconi anemia (FA). (2020-11-23)

Dietary supplement may help in the treatment of fatty liver
A recent study by researchers at the University of Jyväskylä was successful in partially preventing fatty liver disease in rats. Rats with fatty liver disease were fed with a dietary supplement that is known to increase the growth of good bacteria in the gut. Simultaneous with the increased abundance of the bacteria, the liver fat content decreased significantly. In addition, preliminary results from a human study seem promising. (2020-11-04)

Eating less suppresses liver cancer due to fatty liver
Liver cancer from too much fat accumulation in the liver has been increasing in many countries including Japan. In order to change this unfortunate state of affairs, it is important to improve the prognosis of non-alcoholic fatty liver disease. Fatty liver is often improved through eating less, getting more exercise, and reducing body weight. The research group posed the question, ''Can eating less also suppress liver cancer caused by fatty liver?'' (2020-10-29)

Liver cancer diagnoses and deaths impacted by geography and household income
An analysis of information from a large U.S. cancer database indicates that patients with liver cancer from rural regions and lower income households often have more advanced cancer at the time of diagnosis and face a higher risk of death compared with other patients. The findings are published early online in CANCER, a peer-reviewed journal of the American Cancer Society (ACS). (2020-10-26)

Acta Pharmaceutica Sinica B Volume 10, Issue 8 publishes
The Journal of the Institute of Materia Medica, the Chinese Academy of Medical Sciences and the Chinese Pharmaceutical Association, Acta Pharmaceutica Sinica B (APSB) is a monthly journal, in English, which publishes significant original research articles, rapid communications and high quality reviews of recent advances in all areas of pharmaceutical sciences -- including pharmacology, pharmaceutics, medicinal chemistry, natural products, pharmacognosy, pharmaceutical analysis and pharmacokinetics. (2020-10-20)

No stain? No sweat: Terahertz waves can image early-stage breast cancer without staining
A team of researchers at Osaka University, in collaboration with the University of Bordeaux and the Bergonié Institute in France, has succeeded in terahertz imaging of early-stage breast cancer less than 0.5 mm without staining. Differences in terahertz intensity distributions also suggest the possibility of quantitative determination of cancer malignancy. Their work provides a breakthrough towards rapid and precise on-site diagnosis of various types of cancer and accelerates the development of innovative terahertz diagnostic devices. (2020-10-20)

Oncotarget: Geriatric nutritional risk index - prognostic marker of esophageal carcinoma
Oncotarget Volume 11, Issue 29 reported that In multivariate analyses, serum albumin, GNRI, pathological tumor-node-metastasis stage, and tumor differentiation were independent prognostic factors for CSS. (2020-10-16)

Pancreatic cancer: Subtypes with different aggressiveness discovered
To date, no targeted personalized therapies for pancreatic cancer exist. Heidelberg Scientists have now succeeded for the first time in defining two differently aggressive molecular subtypes of pancreatic carcinoma. This provides new insights into the origin of the tumors. In the more aggressive group of tumors, a phenomenon known as 'viral mimicry' leads to a cancer-promoting inflammatory reaction. This could possibly be the basis for the development of a targeted, subtype-oriented therapy. (2020-10-15)

Oncotarget: miR-708-5p targets oncogenic prostaglandin E2 production in lung cancer cell
Volume 11, Issue 26 of Oncotarget reported that Lung cancer is of particular importance, as it is the deadliest cancer worldwide. (2020-10-13)

Even mild fatty liver disease is linked to increased mortality
Non-alcoholic fatty liver disease, NAFLD, affects nearly one in four adults in Europe and the U.S. Earlier research has demonstrated an increased risk of death in patients with NAFLD and advanced fibrosis or cirrhosis. Now, researchers at Karolinska Institutet in Sweden and Massachusetts General Hospital in the U.S. show that mortality increases with disease severity, but even mild fatty liver disease is linked to higher mortality. The findings have been published in the journal Gut. (2020-10-12)

Oncotarget: Characterization of porcine hepatocellular carcinoma for liver cancer
Volume 11, Issue 28 of Oncotarget features ''Development and comprehensive characterization of porcine hepatocellular carcinoma for translational liver cancer investigation'' by Gaba et, al. which reported that reliable development of Oncopig HCC cell lines was demonstrated through hepatocyte isolation and Cre recombinase exposure across 15 Oncopigs. (2020-10-10)

Oncotarget: Rapid onset type 1 diabetes with anti-PD-1 directed therapy
Volume 11, Issue 28 of Oncotarget features 'Rapid onset type 1 diabetes with anti-PD-1 directed therapy', by Yun et al. and reported that Type 1 diabetes is a rare immune-related adverse event caused by checkpoint inhibitors with serious risk for diabetic ketoacidosis. (2020-10-09)

Urine-based liquid biopsy test outperforms urine cytology in detecting bladder cancer
Analysis of DNA copy number variants (CNVs) in the cells exfoliated in urine showed better sensitivity and similar specificity in detecting urothelial carcinoma compared with urine cytology (2020-10-09)

Genetic test identifies invasive lobular carcinomas that are at high risk of recurring
New results to be presented at the 12th European Breast Cancer Conference show that a test, which looks at the activity of 70 genes in breast cancer tissue, is possible to use in the clinic to identify patients with invasive lobular carcinoma (ILC) that is at high risk of recurring and progressing. (2020-09-30)

Immunotherapy improves survival in advanced bladder cancer patients
An immunotherapy drug called 'avelumab' has been shown to significantly improve survival in patients with the most common type of bladder cancer, according to results from a phase III clinical trial led by Queen Mary University of London and Barts Cancer Centre, UK. (2020-09-18)

Page 1 of 25 | 1000 Results
   First   Previous   Next      Last   
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.